2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at h

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references 18

          • Record: found
          • Abstract: found
          • Article: not found

          Outpatient glycemic control with a bionic pancreas in type 1 diabetes.

          The safety and effectiveness of automated glycemic management have not been tested in multiday studies under unrestricted outpatient conditions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The T1D Exchange clinic registry.

            The T1D Exchange includes a clinic-based registry, a patient-centric web site called Glu, and a biobank. The aim of the study was to describe the T1D Exchange clinic registry and provide an overview of participant characteristics. Data obtained through participant completion of a questionnaire and chart extraction include diabetes history, management, and monitoring; general health; lifestyle; family history; socioeconomic factors; medications; acute and chronic diabetic complications; other medical conditions; and laboratory results. Data were collected from 67 endocrinology centers throughout the United States. We studied 25,833 adults and children with presumed autoimmune type 1 diabetes (T1D). Participants ranged in age from less than 1 to 93 yr, 50% were female, 82% were Caucasian, 50% used an insulin pump, 6% used continuous glucose monitoring, and 16% had a first-degree family member with T1D. Glycosylated hemoglobin at enrollment averaged 8.3% and was highest in 13 to 25 yr olds. The prevalence of renal disease was ≤4% until T1D was present for at least 10 yr, and retinopathy treatment was ≤2% until T1D was present for at least 20 yr. A severe hypoglycemic event (seizure or coma) in the prior 12 months was reported by 7% of participants and diabetic ketoacidosis in the prior 12 months by 8%. The T1D Exchange clinic registry provides a database of important information on individuals with T1D in the United States. The rich dataset of the registry provides an opportunity to address numerous issues of relevance to clinicians and patients, including assessments of associations between patient characteristics and diabetes management factors with outcomes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Nocturnal glucose control with an artificial pancreas at a diabetes camp.

              Recent studies have shown that an artificial-pancreas system can improve glucose control and reduce nocturnal hypoglycemia. However, it is not known whether such results can be replicated in settings outside the hospital.
                Bookmark

                Author and article information

                Journal
                Diabetes, Obesity and Metabolism
                Diabetes Obes Metab
                Wiley
                14628902
                April 2019
                April 2019
                December 21 2018
                : 21
                : 4
                : 822-828
                Affiliations
                [1 ]Children's Hospital “Auf der Bult,” Diabetes-Center for Children and Adolescents; Hannover Germany
                [2 ]Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel; Petah Tikvah Israel
                [3 ]DreaMed Diabetes Ltd; Petah Tikvah Israel
                [4 ]Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases; University Children's Hospital, UMC Ljubljana; Ljubljana Slovenia
                Article
                10.1111/dom.13585
                © 2018

                Comments

                Comment on this article